Juan Andres, Chief Operating Officer of Moderna, Inc., filed a Form 4 on November 9, 2026, disclosing the acquisition of stock options and restricted stock units on November 5, 2026 under NASDAQ:MRNA.

Key Highlights

  • Reporting person: Juan Andres, identified as Chief Operating Officer of Moderna, Inc.
  • Stock option grant: 7,898 stock options (right to buy) acquired on November 5, 2026, with an exercise price of $241.46 and an expiration date of November 5, 2036.
  • RSU grant: 16,955 restricted stock units acquired on November 5, 2026, converting into common stock on a one-for-one basis.
  • Vesting schedule: For both awards, 25% vests on November 5, 2027, with the remainder vesting in twelve equal quarterly installments thereafter.
  • Price of derivative securities: Both the stock options and restricted stock units were acquired at a price of $0, as reported in the filing.
  • Transaction codes: Both transactions are coded "A" (acquired) and held directly.

Moderna COO Andres Receives Equity Awards Totaling 7,898 Options and 16,955 RSUs

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2026, Juan Andres, the Chief Operating Officer of Moderna, Inc. (NASDAQ:MRNA), received two equity awards on November 5, 2026. The first award consists of 7,898 stock options (right to buy) with an exercise price of $241.46 per share and an expiration date of November 5, 2036. The second award consists of 16,955 restricted stock units, which the filing states convert into common stock on a one-for-one basis.

The filing discloses that both awards share the same vesting structure: 25% of each award will vest and become exercisable on November 5, 2027, with the remaining portion vesting in twelve equal quarterly installments thereafter. The price of each derivative security at acquisition is listed as $0 in the filing. Following the reported transactions, Andres beneficially owns 7,898 stock options and 16,955 restricted stock units, all held directly.

The Form 4 was signed by James Dillon as Attorney-in-Fact for the reporting person on November 9, 2026. The filing does not indicate that the transactions were made pursuant to a Rule 10b5-1(c) plan, as that checkbox on the form was not selected.

What Was Disclosed

Moderna's Chief Operating Officer Juan Andres disclosed the acquisition of 7,898 stock options at an exercise price of $241.46 and 16,955 restricted stock units on November 5, 2026, both vesting 25% on November 5, 2027, with the balance in quarterly installments.